Blurbs

Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Zimmer Biomet Holdings (ZBH) and Aptose Biosciences (APTO)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Incyte (INCYResearch Report), Zimmer Biomet Holdings (ZBHResearch Report) and Aptose Biosciences (APTOResearch Report).

Incyte (INCY)

In a report issued on August 2, Brian Abrahams from RBC Capital maintained a Buy rating on Incyte, with a price target of $82.00. The company’s shares closed last Wednesday at $72.54.

According to TipRanks.com, Abrahams is a 2-star analyst with an average return of -0.1% and a 45.8% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Karyopharm Therapeutics, and Vertex Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Incyte with a $85.08 average price target, representing a 18.9% upside. In a report issued on July 20, Bank of America Securities also maintained a Buy rating on the stock with a $91.00 price target.

See the top stocks recommended by analysts >>

Zimmer Biomet Holdings (ZBH)

RBC Capital analyst Shagun Singh Chadha maintained a Hold rating on Zimmer Biomet Holdings on August 2 and set a price target of $128.00. The company’s shares closed last Wednesday at $115.61.

According to TipRanks.com, Chadha is a 1-star analyst with an average return of -8.1% and a 19.0% success rate. Chadha covers the Healthcare sector, focusing on stocks such as Edwards Lifesciences, Intuitive Surgical, and Boston Scientific.

The word on The Street in general, suggests a Hold analyst consensus rating for Zimmer Biomet Holdings with a $123.80 average price target, implying a 7.6% upside from current levels. In a report issued on July 20, Truist Financial also maintained a Hold rating on the stock with a $115.00 price target.

Aptose Biosciences (APTO)

RBC Capital analyst Gregory Renza maintained a Buy rating on Aptose Biosciences on August 2 and set a price target of $6.00. The company’s shares closed last Wednesday at $0.77, close to its 52-week low of $0.71.

According to TipRanks.com, Renza has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -5.9% and a 33.1% success rate. Renza covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Verrica Pharmaceuticals, and ACADIA Pharmaceuticals.

Aptose Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $8.80, representing a 1028.2% upside. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $12.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on INCY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos